Abstract
Background: Levofloxacin is a broad spectrum anti-infective agent, which is rapidly and completely absorbed after oral administration. The half life of Levofloxacin is 6-8 h after conventional dosing. The objective of the present work was to develop Levofloxacin nanoparticles to retain the dosage form in the absorption site more than the half life of the drug, enhance the bioavailability of drugs, reduce dose frequency, toxicity and patient compliance. Methods: The compositions of different formulations of Levofloxacin nanoparticles by the ionic gelation method using biodegradable polymer chitosan and tripolyphosphate as cross linking agent. Result and Discussion: The particle size lies of the prepared nanoparticles between 199 and 369 nm and the drug content found between 51.13± 0.28 and 71.12 ± 0.14 %. The particle size of nanoparticles increased with increasing concentration of polymer matrix density and this may be due to the increased viscosity of the inner phase and decreased with increasing concentration of β-cyclodextrin. Scanning electron microscopy indicated that the prepared nanoparticles were discrete, uniform and spherical with a smooth surface. The in vitro release showed that the drug release from the prepared nanoparticles was characterized by an initial fast release and followed by a delayed release phase. During and at the end of the accelerated stability study, the tested formulation showed almost same drug content, in vitro drug release and no colour changes were observed from that observed at the opening of the study. Conclusion: Among all the formulations (GIA, GIB, GIC, GID, GIE and GIF), the formulations G1C, G1E and G1F followed the drug release in a controlled manner. The in vitro release profile showed that this is a potential drug delivery for Levofloxacin and has to confirm in the in vivo settings as a separate investigation in future. Key words: Controlled drug delivery, In vitro drug release, Nanoparticle, Particle size, Stability studies, Surface morphology
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
